GRACE :: Global Resource for Advancing Cancer Education
  • Recent GRACE News & Posts

    • Targeted Therapies in a Post-Operative/Adjuvant Setting [GRACE :: Lung Cancer]
      Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
    • Induction Chemotherapy Followed by Chemo/Radiation for Stage III NSCLC [GRACE :: Lung Cancer]
      Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
    • Management of Locally Advanced NSCLC in the Elderly and Frail [GRACE :: Lung Cancer]
      Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
    • Defining Resectability in Stage IIIA Lung Cancer [GRACE :: Lung Cancer]
      Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
    • Neoadjuvant Chemotherapy vs. Chemo/Radiation for Stage IIIA NSCLC [GRACE :: Lung Cancer]
      Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
    • Overall Management for Stage IIIA Disease [GRACE :: Lung Cancer]
      Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.
    • Managing Three Compartments in Stage III Disease (Local, Distant, CNS) [GRACE :: Lung Cancer]
      Dr. Mark Socinski, University of Pittsburgh Medical Center, defines the three compartments in stage III (locally advanced) NSCLC, each of which must be treated.
    • Heterogeneity of Stage III NSCLC/Defining Resectability for Locally Advanced NSCLC [GRACE :: Lung Cancer]
      Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the different types of stage III (locally advanced) NSCLC, and states which of these types tend to be resectable.
    • What is V20 and Why Do Radiation Dose & Field Size Matter? [GRACE :: Lung Cancer]
      Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines the V20 standard for lung radiation and outlines the advantages of limiting dose and field size in lung radiation therapy.
    • High vs. Standard Dose Chest Radiation in Stage III Lung Cancer [GRACE :: Lung Cancer]
      Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, provides trial evidence showing that patients may not benefit from high dose chest radiation therapy vs. standard dose therapy.
    • SBRT for Oligometastatic Lung Cancer [GRACE :: Lung Cancer]
      Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.
    • SBRT for Medically Inoperable Stage I Lung Cancer [GRACE :: Lung Cancer]
      Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, describes the history and current use of stereotactic radiation therapy for inoperable lung lesions.Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, des

Ask Us, Q&A

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Join the GRACE Faculty

Lung/Thoracic Cancer Blog
Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog

Subscribe to the GRACEcast Podcast on iTunes

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Recent GRACE Forum Topics

Recent GRACE Forum Replies

Other Resources

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243